tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Erythema D004890 22 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cavaillé-Coll MW and Elashoff MR Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. 1998 Transplantation pmid:9448161
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Ellis D et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. 1999 Transplantation pmid:10532541
First MR and Fitzsimmons WE New drugs to improve transplant outcomes. 2004 Transplantation pmid:15201693
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Jain AB et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. 2004 Transplantation pmid:15077034
Waldman WJ et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. 2001 Transplantation pmid:11707749
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Ravindran VK et al. Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. 2009 Transplantation pmid:19543067
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Heilman RL et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. 2012 Transplantation pmid:22067270
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
Mourad G et al. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. 2017 Transplantation pmid:27547871
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Reddy KS et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. 2000 Transplantation pmid:10653379
Jevnikar A et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. 2008 Transplantation pmid:18852662
Ravaioli M et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. 2015 Transplantation pmid:25757214
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Ciancio G et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. 2004 Transplantation pmid:15316372
Naesens M and Sarwal MM Monitoring calcineurin inhibitor therapy: localizing the moving target. 2010 Transplantation pmid:20458272
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
McLaren A Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. 2003 Transplantation pmid:14705621
Florescu DF et al. Adenovirus infections in pediatric small bowel transplant recipients. 2010 Transplantation pmid:20467354
Jun KR et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. 2009 Transplantation pmid:19384171
Roberts CA et al. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. 2002 Transplantation pmid:12364862
Vafadari R et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. 2012 Transplantation pmid:22643331
Morales JM et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. 2008 Transplantation pmid:18724234
Gallon LG et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. 2007 Transplantation pmid:17519781
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Radkowski M et al. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. 1998 Transplantation pmid:9753352
Egashira K et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. 2003 Transplantation pmid:12698101
Hu H et al. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 2003 Transplantation pmid:12698107
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575